Sugi Predict

Sugi Predict / Compounds / SCHEMBL2852428

SCHEMBL2852428

SCHEMBL2852428

C[C@H](Nc1nc2ccc(Oc3cc(Cl)ncn3)cc2s1)C1CCCCC1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.44
▸ RAB9A P51151 3/20 0.44
▸ MAPT P10636 2/20 0.44
▸ PKM P14618 1/20 0.44
▸ CSF1R P07333 9/20 0.42
▸ PI4KA P42356 2/20 0.42
▸ PI4KB Q9UBF8 2/20 0.42
▸ PIP5K1C O60331 1/20 0.42
▸ PIK3CG P48736 1/20 0.42
▸ PDGFRB P09619 2/20 0.41
▸ KIT P10721 2/20 0.41
▸ PDGFRA P16234 2/20 0.41
▸ FLT3 P36888 2/20 0.41
▸ ITK Q08881 1/20 0.40
▸ USP30 Q70CQ3 2/20 0.40
▸ MAOA P21397 1/20 0.39
▸ MAOB P27338 1/20 0.39
▸ ATAD2 Q6PL18 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2852429 1.00 NPC1 (0.44) NPC1RAB9AMAPTPKMCSF1R
SCHEMBL2677235 0.87 CSF1R (0.47) NPC1RAB9AMAPTPKMCSF1R
SCHEMBL2677238 0.87 CSF1R (0.47) NPC1RAB9AMAPTPKMCSF1R
SCHEMBL2846296 0.86 CSF1R (0.46) NPC1RAB9AMAPTPKMCSF1R
SCHEMBL2846300 0.86 CSF1R (0.46) NPC1RAB9AMAPTPKMCSF1R
SCHEMBL2843313 0.83 PI4KA (0.41) NPC1RAB9AMAPTPKMCSF1R
SCHEMBL2843310 0.83 PI4KA (0.41) NPC1RAB9AMAPTPKMCSF1R
SCHEMBL2845197 0.81 NPC1 (0.43) NPC1RAB9AMAPTPKMCSF1R
SCHEMBL2676548 0.81 NPC1 (0.61) NPC1RAB9AMAPTPKMITK
SCHEMBL2676546 0.81 NPC1 (0.61) NPC1RAB9AMAPTPKMITK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 — — US claimed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 — — US claimed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 — — US disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 — — US disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 — — US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 — — US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 — — US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 — — US disclosed
WO-2008144062-A1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2008-11-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE CSF1R, CSF3R, FLT3 NPC1 2714/4885RAB9A 1826/4885MAPT 3767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.